Key result
Most prescribers demonstrated knowledge of the risks and safe use of albiglutide, with correct response rates for individual questions ranging from 68.2% to 98.1% across the 18-month and 3-year surveys.
Cross-Sectional (n=404)
Survey results indicate that most prescribers are knowledgeable regarding the risks of medullary thyroid carcinoma and pancreatitis associated with albiglutide, though some gaps remain regarding the appropriate patient population.
Answers are grounded in this paper and cite their sources.
High prescriber knowledge of albiglutide risks supports effective education; leaves open whether gaps affect real-world prescribing.
BACKGROUND: The risk of pancreatitis and potential risk of medullary thyroid carcinoma associated with glucagon-like peptide-1 receptor agonists prompted the US Food and Drug Administration to require a Risk Evaluation and Mitigation Strategy for albiglutide, including education for prescribers and subsequent assessment of their knowledge of the risks and safe use of albiglutide via a quantitative survey. OBJECTIVE: The objective of this study was to assess prescribers' knowledge of the risks related to medullary thyroid carcinoma, pancreatitis, and the appropriate patient population for albiglutide. METHODS: Two Risk Evaluation and Mitigation Strategy surveys were conducted 18 months and 3 years after albiglutide was launched. Primary analyses evaluated correct response rates for each question. Secondary analyses evaluated the number of correct responses and the percentage of respondents scoring at/above the target comprehension thresholds (75% at 18 months; 80% at 3 years), which were selected based on discussion with the Food and Drug Administration and current standards for Risk Evaluation and Mitigation Strategy assessments, for each key risk message. RESULTS: The correct response rate for individual questions ranged from 68.2 to 97.9% (18-month survey) and from 69.4 to 98.1% (3-year survey). For the secondary analysis, 79.5, 86.7, and 86.7% of respondents in the 18-month survey answered ≥ 75% of the questions correctly and 70.8, 90.9, and 54.1% of respondents in the 3-year survey answered ≥ 80% of the questions correctly for key risk messages related to medullary thyroid carcinoma, pancreatitis, and appropriate patient population, respectively. CONCLUSIONS: Survey results indicated most, but not all, prescribers are knowledgeable regarding the risks and safe use of albiglutide. Additional education to address gaps in knowledge could further improve risk mitigation.
No takes yet. Share an insight, caveat, or question.
Koro et al. (2017) conducted a cross-sectional in Prescribers of albiglutide (n=404). Risk Evaluation and Mitigation Strategy (REMS) education for albiglutide was evaluated on Correct response rates for individual questions regarding the risks and safe use of albiglutide. Most prescribers demonstrated knowledge of the risks and safe use of albiglutide, with correct response rates for individual questions ranging from 68.2% to 98.1% across the 18-month and 3-year surveys.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: